Skip to content
India Glycols logo

India Glycols

INDIAGLYCO NSE
₹309.20 −14.55 (−4.49%)
P/E
6.44
View as Markdown
MCP
Close 4 Nov 2026 ₹309.20 +73.00 +30.9% since 2 Sep 2026
Start ₹236.20

Key Fundamentals

MicrocapBeveragesFMCG

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
12.40%
Debt to Equity
0.58
EPS (TTM)
₹48.02
Book Value
₹437.55
Market Cap
—
P/E (TTM)
6.44
P/B
0.71
ROE
11.30%
Dividend Yield
2.32%
EBITDA
₹654 Cr
52W High
₹1,222.00
52W Low
₹217.00
Day Range
₹304.00 – ₹321.90
Volume
6,97,978

Peer Comparison

Fast Moving Consumer Goods › Consumer Goods › Breweries & Distilleries

India Glycols peer comparison
United Spirits
₹1,419.3054.78₹1,00,884 Cr11.391.23%21.40%26.40%₹12,626 Cr₹1,884 Cr
Radico Khaitan
₹4,396.5083.70₹57,961 Cr16.050.21%20.30%24.20%₹6,228 Cr₹704 Cr
United Breweries
₹1,204.5080.51₹32,064 Cr6.980.84%7.69%10.70%₹9,442 Cr₹395 Cr
Allied Blenders & Distillers
₹697.5088.29₹19,494 Cr11.890.78%14.30%18.40%₹3,979 Cr₹210 Cr
Tilaknagar Industries
₹473.60—₹11,718 Cr3.890.22%12.60%11.40%₹3,016 Cr−₹35 Cr
Piccadily Agro Industries
₹594.3041.68₹5,848 Cr6.500.17%17.40%18.00%₹1,075 Cr₹141 Cr
India Glycols (this company)
₹309.206.44₹2,148 Cr0.712.32%11.30%12.40%₹4,301 Cr₹317 Cr
Globus Spirits
₹669.1019.32₹2,115 Cr1.610.99%8.76%11.20%₹2,799 Cr₹99 Cr
Median 8 companies₹683.3054.78₹15,606 Cr6.740.81%13.45%15.20%₹4,140 Cr₹264 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

49 Average

Data confidence 100/100

Category scores

Quality
60
Good
Returns, margins, earnings quality 22% weight
Valuation
71
Strong
Cheap vs sector & own history 24% weight
Growth
61
Good
Sales & profit trajectory 9% weight
Financial Health
32
Poor
Solvency, leverage, coverage 9% weight
Momentum
2
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Stock is trading at 0.73 times its book value

Weaknesses

1
  • Company has a low return on equity of 10.4% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish6121
OscillatorsBearish261
Moving AveragesBearish460

Key readings

RSI (14)
49.65
Neutral
MACD (12,26,9)
7.62
Bearish
SMA (50)
—
Neutral
SMA (200)
—
Neutral

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+6.12%
5Y+12.69%
3Y+16.68%
1Y+11.76%
TTM+12.01%

Net profit

Net profit growth by window
10YTurned to profit
5Y+17.29%
3Y+27.61%
1Y+26.84%
TTM+29.92%

Operating cash flow

Operating cash flow growth by window
10Y−4.60%
5Y+41.20%
3Y+33.12%
1Y+112.43%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+7.88 pp
5Y+2.85 pp
3Y+3.90 pp
1Y+1.85 pp
TTM+1.60 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹2,500 Cr
Mar 2018₹3,034 Cr
Mar 2019₹3,357 Cr
Mar 2020₹2,735 Cr
Mar 2021₹2,317 Cr
Mar 2022₹2,868 Cr
Mar 2023₹2,651 Cr
Mar 2024₹3,294 Cr
Mar 2025₹3,768 Cr
Mar 2026₹4,211 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹35.00 Cr
Mar 2018₹97.00 Cr
Mar 2019₹133 Cr
Mar 2020₹115 Cr
Mar 2021₹132 Cr
Mar 2022₹340 Cr
Mar 2023₹141 Cr
Mar 2024₹173 Cr
Mar 2025₹231 Cr
Mar 2026₹293 Cr

AI Analysis — Bull vs Bear

Generated 31 Jul 2026
AI opinion · based on fundamentals
Risk medium

India Glycols Ltd is a diversified green petrochemical and potable spirits company trading at a market cap of ₹7,678 Cr with a P/E of 25.9x. The company has delivered 17% compounded sales growth over 3 years and 39% compounded profit growth over the same period, though its return on equity remains modest at around 10-11%. Its debt-to-equity ratio stands near 0.86x and the stock trades at 2.58x book value.

Bull Case 8
  • Strong 3-year compounded profit growth of 39% indicates improving profitability and operating leverage across business segments
  • TTM revenue growth of 12% and 3-year compounded sales CAGR of 17% demonstrate consistent top-line momentum
  • Stock has delivered 54% CAGR over 3 years and 37% CAGR over 10 years, reflecting sustained long-term wealth creation
  • FY26 net profit surged 56.5% YoY to ₹282 Cr from ₹180 Cr in FY25, showing an acceleration in earnings trajectory
  • India's only integrated green petrochemical company using renewable agricultural feedstock, positioning it well for ESG-driven demand and ethanol-blending policies
  • Diversified revenue streams across Bio-Based Chemicals, Potable Spirits, and Biopharma segments reduce single-segment dependency
  • Dividend payout increased from 80% to 100% of face value in FY25, with total dividend outgo rising to ₹30.96 Cr from ₹24.77 Cr, signaling management confidence
  • 10-year compounded profit CAGR of 74% reflects a long runway of earnings expansion from a low base
Bear Case 7
  • Return on equity has averaged only 10% over 3, 5, and 10 years, indicating modest capital efficiency relative to the 25.9x P/E multiple
  • Debt-to-equity ratio near 0.86x implies meaningful financial leverage, increasing vulnerability to interest rate hikes or earnings slowdowns
  • Dividend yield of only 0.66% offers limited income support at current valuations
  • 5-year compounded profit growth of just 14% is significantly lower than the 3-year figure of 39%, indicating earnings volatility across cycles
  • 10-year compounded sales CAGR of only 6% suggests historically sluggish top-line growth before the recent acceleration
  • Commodity-linked business exposed to ethylene oxide and molasses price fluctuations, which can compress margins in adverse cycles
  • Q3FY25 revenue of ₹975 Cr came below analyst estimates, highlighting execution risk and demand uncertainty in certain quarters

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

94d ago

TL;DR: India Glycols is progressing well on its corporate restructuring front with NCLT approval for the demerger of Bio Pharma and Spirits businesses, a move that should unlock standalone value. No visible headwinds in recent news flow. The management reshuffle at Ennature Bio Pharma signals preparation for post-demerger operations. The trend is constructive as the company moves toward a leaner, more focused structure.

Positives 1
  • NCLT approves demerger scheme Jul 17

    NCLT Allahabad Bench sanctioned the demerger of India Glycols' Bio Pharma and Spirits undertakings on July 17, 2026, enabling the company to unlock value through separate focused entities.

Neutral 2
  • Director appointed at subsidiary Aug 1

    Akshay Bansal appointed as Additional Director and KMP at subsidiary Ennature Bio Pharma effective July 31, 2026, for a five-year term, addressing regulatory observations on the Scheme of Arrangement.

  • 42nd AGM scheduled Aug 19 Jul 22

    India Glycols will hold its 42nd AGM on August 19, 2026, via video conferencing to cover FY 2025-26 results.

Quarterly Results

₹ Cr
INDIAGLYCO quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
689
775
904
926
969
961
975
863
1,040
1,092
1,102
976
1,130
Expenses
589
679
802
822
843
845
852
717
891
935
927
810
961
Operating Profit
100
96
102
105
126
116
124
146
150
158
175
166
170
OPM %
15%
12%
11%
11%
13%
12%
13%
17%
14%
14%
16%
17%
15%
Other Income
12
10.73
9
10
14
15
19
13
20
14
3
14
21
Interest
28
29
31
33
36
40
44
45
45
49
47
26
25
Depreciation
21
28
26
26
28
28
27
33
34
38
41
41
42
PBT
64
49.23
54
56
76
63
71
82
91
84
91
112
123
Tax %
20%
24%
23%
24%
20%
22%
20%
22%
19%
22%
25%
23%
21%
Net Profit
51
38
42
42
60
50
57
64
73
65
68
87
97
EPS (₹)
8.25
6.13
6.71
6.81
9.74
8.02
9.16
10.33
11.81
10.51
10.09
12.97
14.45

Profit & Loss

₹ Cr
INDIAGLYCO profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
2,579
2,324
2,500
3,034
3,357
2,735
2,317
2,868
2,651
3,294
3,768
4,211
4,301
Expenses
2,455
2,149
2,263
2,712
2,941
2,433
2,026
2,599
2,346
2,879
3,257
3,562
3,632
Operating Profit
124
175
237
322
416
303
291
269
305
415
511
649
669
OPM %
4.8%
8%
9%
11%
12%
11%
13%
9%
12%
13%
14%
15%
16%
Other Income
−16
−47
7
23
17
24
15
260
54
30
61
50
51
Interest
163
139
127
125
143
97
83
70
100
121
164
167
148
Depreciation
89
69
72
73
76
78
80
80
94
101
115
155
163
PBT
−144
−81
45
147
213
153
143
379
165
223
292
377
410
Tax %
−38%
−30%
22%
34%
38%
25%
8%
10%
15%
23%
21%
22%
—
Net Profit
−89
−57
35
97
133
115
132
340
141
173
231
293
316
EPS (₹)
−14.3
−9.16
5.65
15.57
21.39
18.49
21.23
54.81
20.17
27.9
37.25
43.7
48.02
Div. Payout %
0%
0%
9%
13%
14%
16%
14%
7%
19%
14%
13%
17%
—

Balance Sheet

₹ Cr
INDIAGLYCO balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
31
31
31
31
31
31
31
31
31
31
31
34
Reserves
266
687
721
814
932
1,003
1,138
1,761
1,870
2,020
2,225
2,899
Borrowings
2,264
1,236
1,095
834
1,000
999
1,137
1,047
1,112
1,348
1,892
1,691
Other Liabilities
593
1,665
1,645
1,742
1,821
2,053
1,814
1,792
1,845
2,218
2,029
1,900
Total Liabilities
3,154
3,620
3,492
3,421
3,784
4,086
4,119
4,631
4,858
5,617
6,176
6,523
Fixed Assets
1,146
2,029
2,111
2,156
2,173
2,228
2,193
2,318
2,717
3,205
3,829
4,554
CWIP
162
181
91
89
137
172
126
243
125
84
98
37
Investments
4
28
25
24
21
26
27
336
318
335
381
389
Other Assets
1,843
1,382
1,265
1,152
1,453
1,660
1,774
1,734
1,698
1,993
1,867
1,543
Total Assets
3,154
3,620
3,492
3,421
3,784
4,086
4,119
4,631
4,858
5,617
6,176
6,523

Cash Flow

₹ Cr
INDIAGLYCO cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−171
1,231
302
502
147
343
137
116
326
439
362
769
Investing
175
−78
−40
−103
−128
−151
−148
76
−330
−503
−736
−767
Financing
−4
−1,168
−263
−399
3
−216
11
−189
−1
90
354
23
Net Cash Flow
0
−15
−1
0
22
−23
0
4
−5
25
−20
25
Free Cash Flow
−53
1,137
260
373
9
193
−11
−264
−109
−103
−391
−47
CFO/EBITDA
−136
705
127
156
37
127
53
51
123
108
75
122

Ratios

INDIAGLYCO financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
62
57
57
40
35
76
57
51
59
43
35
30
Inventory Days
109
128
129
87
124
146
166
148
209
224
209
139
Days Payable
55
120
144
152
143
155
158
137
209
222
175
123
Cash Conversion Cycle
115
66
42
−25
17
67
65
62
60
44
70
47
Working Capital Days
−110
−94
−117
−78
−50
−64
−79
−31
−46
−63
−56
−49
ROCE %
3%
5%
9%
15%
20%
14%
10%
9%
8%
11%
12%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view India Glycols insights

65 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 59.63%
  • Public 27.12%
  • Others 7.43%
  • DIIs 3.05%
  • FIIs 2.76%

No promoter shares pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about India Glycols

What does India Glycols Ltd do?
Established in 1988, India Glycols Ltd. is engaged in the manufacturing of green technology-based bulk, specialty & performance chemicals, and natural gums, spirits, industrial gases, sugar, and nutraceuticals.
Where is India Glycols Ltd (INDIAGLYCO) listed?
India Glycols Ltd trades as INDIAGLYCO on the NSE and under code 500201 on the BSE.
Which sector does India Glycols Ltd belong to?
India Glycols Ltd is classified under the Consumer Goods sector, in the Breweries & Distilleries industry.
What is the PE ratio of India Glycols Ltd?
India Glycols Ltd trades at a PE ratio of 6.44 as of 4 Nov 2026, on earnings per share of ₹48.02, against a book value of ₹437.55 per share.
What is the 52-week high and low of India Glycols Ltd?
Over the last 52 weeks India Glycols Ltd has traded between ₹217 and ₹1,222 as of 4 Nov 2026.
Does India Glycols Ltd pay dividends?
India Glycols Ltd has a dividend yield of 2.32%.
What is the Return on Equity (ROE) of India Glycols Ltd?
India Glycols Ltd reported a return on equity of 11.30%. Its debt-to-equity ratio is 0.58.

Company Information

Established in 1988, India Glycols Ltd. is engaged in the manufacturing of green technology-based bulk, specialty & performance chemicals, and natural gums, spirits, industrial gases, sugar, and nutraceuticals.

Website indiaglycols.com
CEO Mr. Uma Shankar Bhartia
Employees 1,357
Listed 1 Jul 2005
Face Value ₹5

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/INDIAGLYCO.md for India Glycols Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Beverage stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month